Association of sulfonylureas with the risk of dementia: A population‐based cohort study.

Background: Sulfonylureas are oral glucose‐lowering medications positioned as a second‐line therapy for type 2 diabetes. Evidence relating them to cognitive decline has been mixed. The objective was to determine whether sulfonylurea use was associated with a differential risk of dementia compared wi...

Descripción completa

Detalles Bibliográficos
Publicado en:Journal of the American Geriatrics Society Vol. 71; no. 10; pp. 3059 - 3071
Autores principales: Wu, Che‐Yuan, Iskander, Carina, Wang, Christa, Xiong, Lisa Y., Shah, Baiju R., Edwards, Jodi D., Kapral, Moira K., Herrmann, Nathan, Lanctôt, Krista L., Masellis, Mario, Swartz, Richard H., Cogo‐Moreira, Hugo, MacIntosh, Bradley J., Rabin, Jennifer S., Black, Sandra E., Saskin, Refik, Swardfager, Walter
Formato: Artículo
Publicado: Wiley-Blackwell Oct2023
Materias:
Acceso en línea:Ver este registro en EBSCOhost
fields @attributes:
  recordID: 1
pdfLink:
plink: https://search.ebscohost.com/login.aspx?direct=true&db=ssf&AN=172913261&site=ehost-live
header:
  @attributes:
    shortDbName: ssf
    uiTerm: 172913261
    longDbName: Social Sciences Full Text (H.W. Wilson)
    uiTag: AN
  controlInfo:
    bkinfo:
    jinfo:
      jid:
        00028614
        20Q
      jtl: Journal of the American Geriatrics Society
      issn: 00028614
      maglogo: Y
    pubinfo:
      dt: Oct2023
      vid: 71
      iid: 10
      pid: 480
      pub: Wiley-Blackwell
    artinfo:
      ui:
        172913261
        10.1111/jgs.18397
      ppf: 3059
      ppct: 12
      formats:
      tig:
        atl: Association of sulfonylureas with the risk of dementia: A population‐based cohort study.
      aug:
        au:
          Wu, Che‐Yuan
          Iskander, Carina
          Wang, Christa
          Xiong, Lisa Y.
          Shah, Baiju R.
          Edwards, Jodi D.
          Kapral, Moira K.
          Herrmann, Nathan
          Lanctôt, Krista L.
          Masellis, Mario
          Swartz, Richard H.
          Cogo‐Moreira, Hugo
          MacIntosh, Bradley J.
          Rabin, Jennifer S.
          Black, Sandra E.
          Saskin, Refik
          Swardfager, Walter
        affil:
          Department of Pharmacology and Toxicology, University of Toronto, Toronto Ontario,, Canada
          Sandra Black Centre for Brain Resilience and Recovery, Hurvitz Brain Sciences Program, Sunnybrook Research Institute, Toronto Ontario,, Canada
          ICES, Toronto Ontario,, Canada
          Divisions of Endocrinology and Obstetric Medicine, Department of Medicine, Sunnybrook Health Sciences Centre, Toronto Ontario,, Canada
          University of Ottawa Heart Institute, University of Ottawa, Ottawa Ontario,, Canada
          School of Epidemiology and Public Health, University of Ottawa, Ottawa Ontario,, Canada
          ICES, Ottawa Ontario,, Canada
          Institute for Health Policy, Management, and Evaluation, University of Toronto, Toronto Ontario,, Canada
          Division of General Internal Medicine, Department of Medicine, University of Toronto, Toronto Ontario,, Canada
          Department of Psychiatry, Sunnybrook Health Sciences Centre, Toronto Ontario,, Canada
          Department of Psychiatry, University of Toronto, Toronto Ontario,, Canada
          KITE University Health Network Toronto Rehabilitation Institute, Toronto Ontario,, Canada
          Toronto Dementia Research Alliance, Toronto Ontario,, Canada
          Department of Medicine (Neurology), Sunnybrook Health Sciences Centre, University of Toronto, Toronto Ontario,, Canada
          Faculty of Education, ICT, and Learning, Østfold University College, Halden, Norway
          Department of Medical Biophysics, University of Toronto, Toronto Ontario,, Canada
          Computational Radiology & Artificial Intelligence (CRAI), Department of Radiology and Nuclear Medicine, Oslo University Hospital, Oslo, Norway
          Harquail Centre for Neuromodulation, Hurvitz Brain Sciences Program, Sunnybrook Research Institute, Toronto Ontario,, Canada
          Rehabilitation Sciences Institute, University of Toronto, Toronto Ontario,, Canada
      su:
        Public health surveillance
        Retrospective studies
        Dementia risk factors
        Alzheimer's disease
        Confidence intervals
        Insulin secretagogues
        Hypoglycemic agents
        Risk assessment
        Type 2 diabetes
        Comparative studies
        Descriptive statistics
        Research funding
        Odds ratio
        Longitudinal method
        Enzyme inhibitors
        Algorithms
        Proportional hazards models
        Disease complications
      sug:
        subj:
          Public health surveillance
          Retrospective studies
          Dementia risk factors
          Alzheimer's disease
          Confidence intervals
          Insulin secretagogues
          Hypoglycemic agents
          Risk assessment
          Type 2 diabetes
          Comparative studies
          Descriptive statistics
          Research funding
          Odds ratio
          Longitudinal method
          Enzyme inhibitors
          Algorithms
          Proportional hazards models
          Disease complications
      keyword:
        dementia
        diabetes
        dipeptidyl peptidase‐4 (DPP4) inhibitors
        sulfonylureas
        dementia
        diabetes
        dipeptidyl peptidase‐4 (DPP4) inhibitors
        sulfonylureas
      ab: Background: Sulfonylureas are oral glucose‐lowering medications positioned as a second‐line therapy for type 2 diabetes. Evidence relating them to cognitive decline has been mixed. The objective was to determine whether sulfonylurea use was associated with a differential risk of dementia compared with dipeptidyl peptidase‐4 (DPP4) inhibitor use. Methods: Using administrative data from residents in Ontario, Canada, adults aged ≥66 years who were new users of a sulfonylurea or a DPP4 inhibitor from June 14, 2011, to March 31, 2021 entered this population‐based retrospective cohort study. Dementia was ascertained using a validated algorithm for Alzheimer's disease and related dementias. Propensity‐score weighted Cox proportional hazards models were used to obtain adjusted hazard ratios (aHR) and confidence intervals (CI) for time to incident dementia. The observation window started at 1 year after cohort entry to mitigate protopathic bias due to delayed diagnosis. The primary analysis used an intention‐to‐treat exposure definition. A separate propensity‐score weighted analysis was conducted to explore within‐class differences in dementia risk among sulfonylurea new users selected from the primary cohort. Results: Among 107,806 DPP4 inhibitor new users and 37,030 sulfonylurea new users, sulfonylureas compared with DPP4 inhibitors were associated with a higher risk of dementia (18.4/1000 person‐years; aHR [95% CI] = 1.09 [1.04–1.15]) over a mean follow‐up of 4.82 years from cohort entry. Glyburide compared to gliclazide exhibited a higher dementia risk (aHR [95% CI] = 1.17 [1.03–1.32]). Conclusion: New use of a sulfonylurea especially glyburide was associated with a higher dementia risk compared with new use of a DPP4 inhibitor in older adults with diabetes. See related Editorial by Lee et al. in this issue.
      pubtype: Academic Journal
      doctype: Article
      src: R
    language: English
    refInfo:
    copyright:
      @attributes:
        flag: N
    holdings:
      @attributes:
        islocal: N